Product Description for HIV-1 + HIV-2
Properties for HIV-1 + HIV-2
|Product Category||Proteins & Growth Factors|
|PDF datasheet||View Datasheet|
|Manufacturer||Acris Antibodies GmbH|
|Material safety datasheet||MSDS for Proteins (de)|
|Purity||>95.0% pure as determined by HPLC-C4 and 10.0% PAGE analysis.
Purification Method: S-Sepharose > Ceramic Hydroxyapatite > S-300 > G-25 Dialysis.
|Application||Antigen in ELISA and Western blots, excellent antigen for early detection of HIV seroconvertors with minimal specificity problems.|
|Background||HIV-1 and HIV-2 appear to package their RNA differently. HIV-1 binds to any appropriate RNA whereas HIV-2 preferentially binds to mRNA which creates the Gag protein itself. This means that HIV-1 is better able to mutate. HIV-2 is transmitted in the same ways as HIV-1: Through exposure to bodily fluids such as blood, semen, tears and vaginal fluids.
Immunodeficiency develops more slowly with HIV-2.
HIV-2 is less infectious in the early stages of the virus than with HIV-1.
The infectiousness of HIV-2 increases as the virus progresses.
Major differences include reduced pathogenicity of HIV-2 relative to HIV-1, enhanced immune control of HIV-2 infection and often some degree of CD4-independence. Despite considerable sequence and phenotypic differences between HIV-1 and 2 envelopes, structurally they are quite similar. Both membrane-anchored proteins eventually form the 6-helix bundles from the N-terminal and C-terminal regions of the ectodomain, which is common to many viral and cellular fusion proteins and which seems to drive fusion.
HIV-1 gp41 helical regions can form more stable 6-helix bundles than HIV-2 gp41 helical regions however HIV-2 fusion occurs at a lower threshold temperature (25°C), does not require Ca2+ in the medium, is insensitive to treatment of target cells with cytochalasin B, and is not affected by target membrane glycosphingolipid composition.
Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.